a Phase 3 Randomized Double Blind Evaluation of LY353381 Compared With Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment
United States: Food and Drug Administration
|Miami, Florida 33176|
|Nashville, Tennessee 37203-1632|
|Metairie, Louisiana 70006|